Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges

Open access
Zhao, Yueshui, Deng, Jian, Rao, Shuangfeng, Guo, Sipeng, Shen, Jing, Du, Fukuan, Wu, Xu, Chen, Yu, Li, Mingxing, Chen, Meijuan, Li, Xiaobing, Li, Wanping, Gu, Li, Sun, Yuhong, Zhang, Zhuo, Wen, Qinglian, Xiao, Zhangang, Li, Jing · 2022 · Cancers

Abstract

Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14174160

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 197

Metadata

Authors
Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., Li, W., Gu, L., Sun, Y., Zhang, Z., Wen, Q., Xiao, Z., & Li, J.
Venue
Cancers
Publisher
MDPI AG
Published
2022-08-27
Volume
14
Issue
17
Pages
4160
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4293659489
Cited by
197
References
13
FWCI
13.59
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. https://app.cochat.ai/papers/10.3390/cancers14174160
The paper
Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., Li, W., Gu, L., Sun, Y., Zhang, Z., Wen, Q., Xiao, Z., & Li, J. (2022). Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Cancers. https://doi.org/10.3390/cancers14174160

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.